These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35801621)

  • 1. An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access Program.
    Guerrini R; Specchio N; Aledo-Serrano Á; Pringsheim M; Darra F; Mayer T; Gil-Nagel A; Polster T; Zuberi SM; Lothe A; Gammaitoni A; Strzelczyk A
    Epilepsia Open; 2022 Dec; 7(4):578-587. PubMed ID: 35801621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
    Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
    Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
    Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
    Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study.
    Specchio N; Pietrafusa N; Doccini V; Trivisano M; Darra F; Ragona F; Cossu A; Spolverato S; Battaglia D; Quintiliani M; Luigia Gambardella M; Rosati A; Mei D; Granata T; Dalla Bernardina B; Vigevano F; Guerrini R
    Epilepsia; 2020 Nov; 61(11):2405-2414. PubMed ID: 32945537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
    Guerrini R; Chiron C; Vandame D; Linley W; Toward T
    Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
    Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
    JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
    Zhang L; Li W; Wang C
    Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenfluramine HCl (Fintepla
    Sullivan J; Scheffer IE; Lagae L; Nabbout R; Pringsheim M; Talwar D; Polster T; Galer B; Lock M; Agarwal A; Gammaitoni A; Morrison G; Farfel G
    Epilepsia; 2020 Nov; 61(11):2396-2404. PubMed ID: 33078386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
    Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
    Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real-world study.
    Gjerulfsen CE; Nikanorova M; Olofsson K; Johannessen Landmark C; Rubboli G; Møller RS
    Epilepsia Open; 2024 Oct; 9(5):1891-1900. PubMed ID: 39140199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany.
    Strzelczyk A; Pringsheim M; Mayer T; Polster T; Klotz KA; Muhle H; Alber M; Trollmann R; Spors H; Kluger G; Kurlemann G; Schubert-Bast S
    Epilepsia; 2021 Oct; 62(10):2518-2527. PubMed ID: 34378197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy?
    Pietrafusa N; Trivisano M; Casellato S; Correale C; Cappelletti S; De Liso P; Onida I; Sotgiu S; Butera A; Specchio N; Vigevano F
    Epilepsia; 2024 Feb; 65(2):e7-e13. PubMed ID: 38065833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: Findings from serial echocardiographic assessments.
    Agarwal A; Farfel GM; Gammaitoni AR; Wong PC; Pinto FJ; Galer BS
    Eur J Paediatr Neurol; 2022 Jul; 39():35-39. PubMed ID: 35640431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial.
    Sullivan J; Lagae L; Cross JH; Devinsky O; Guerrini R; Knupp KG; Laux L; Nikanorova M; Polster T; Talwar D; Ceulemans B; Nabbout R; Farfel GM; Galer BS; Gammaitoni AR; Lock M; Agarwal A; Scheffer IE;
    Epilepsia; 2023 Oct; 64(10):2653-2666. PubMed ID: 37543865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies.
    Sullivan J; Simmons R
    Drugs Today (Barc); 2021 Jul; 57(7):449-454. PubMed ID: 34268532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study.
    Lai WW; Galer BS; Wong PC; Farfel G; Pringsheim M; Keane MG; Agarwal A
    Epilepsia; 2020 Nov; 61(11):2386-2395. PubMed ID: 32809271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
    Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
    Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practice.
    Sullivan J; Perry MS; Wheless JW; Galer B; Gammaitoni A
    Eur J Paediatr Neurol; 2021 Mar; 31():10-14. PubMed ID: 33540241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.